Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis

https://doi.org/10.1016/j.bbalip.2022.159209Get rights and content

Abstract

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing globally. NAFLD includes non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NASH is the pathological form of the disease characterized by liver steatosis, inflammation, cell injury, and fibrosis. A fundamental contributor to NASH is the imbalance between lipid accretion and disposal. The accumulation of liver lipids precipitates lipotoxicity and the inflammatory contributions to disease progression. This review defines the role of dysregulated of lipid disposal in NAFLD pathophysiology. The characteristic changes in mitochondrial oxidative metabolism pathways and the factors promoting these changes across the spectrum of NAFLD severity are detailed. This includes pathway-specific and integrative perturbations in mitochondrial β-oxidation, citric acid cycle flux, oxidative phosphorylation, and ketogenesis. Moreover, well-recognized and emerging mechanisms through which dysregulated mitochondrial oxidative metabolism mediates inflammation, fibrosis, and disease progression are highlighted.

Introduction

The global prevalence of non-alcoholic fatty liver disease (NAFLD) is approximately 20–30 % [1]. NAFLD is an umbrella term encompassing the entire spectrum of the disease [2]. Traditionally, NAFLD is divided into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) [3]. The majority of individuals with NAFLD have NAFL, which is defined as hepatic steatosis (intrahepatic fat ≥5 % of liver weight) in the absence of alternative causal factors such as alcohol, viral infections, or pharmacological agents [4]. NAFL is often regarded as a benign condition given that the majority of individuals with simple steatosis have a low risk for progression to advanced liver disease [5]. In agreement, the accumulation of liver triglycerides, the primary lipid increased in NAFL, is not sufficient to induce hepatocyte dysfunction in experimental models [6], [7]. In contrast to NAFL, NASH is pathological as it is characterized by liver steatosis accompanied by inflammation, hepatocyte damage and/or fibrosis [8], [9], [10]. Currently, 25–30 % of individuals with NAFLD have NASH [8], [9], [10]. It is important to note that NASH is a dynamic disease wherein the defining characteristics may regress to simple steatosis, remain relatively constant, or display progressive advancement of injury, inflammation and fibrosis [11]. Consistent with its progressive characteristics, NASH is a risk factor for developing advanced liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) [12], [13]. In fact, NAFLD is now the second leading indication of liver transplantation and the fastest-growing indication for HCC liver transplantation in the United States [14], [15]. In addition to compromising the well-being of a significant proportion of the population, NAFLD is estimated to be responsible for greater than $100 billion per year in direct medical costs in the United States alone [16]. The significant individual and economic burden is amplified by the fact that there are currently no US Food and Drug Administration-approved pharmacotherapies for NAFLD [17].

The implementation of effective treatments for NAFLD has been challenging due to the complexity of the disease. Genetic variation, age, ethnicity, sex, and co-morbidities all influence NAFLD pathophysiology [2]. Despite the multifactorial nature of this liver disease, a fundamental contributor to NAFLD is an imbalance in hepatic lipid supply, accretion (synthesis and storage), and disposal (export and catabolism) [18]. The prevalence of obesity, hyperlipidemia/dyslipidemia, and type 2 diabetes in NAFLD is estimated at approximately 51 %, 69 %, and 23 %, respectively [1]. Together, these co-morbidities are significant mediators of greater lipid supply to the liver and a remodeled hepatic lipidome. A marked increase in newly synthesized fatty acids via hepatic de novo lipogenesis is another consistent feature of NAFLD that exacerbates lipid deposition [19], [20]. In contrast to the common findings of elevated lipid availability and accretion in NAFLD, fatty acid disposal in hepatic mitochondrial oxidative metabolism pathways exhibit much more functional heterogeneity. This has led to ambiguity as to the role of lipid catabolic pathways in NAFLD and whether they can or should be targeted for therapeutic purposes. Herein, we describe the current state of knowledge regarding the characteristic changes in mitochondrial oxidative metabolism over the natural progression of the disease as well as discuss physiological (hepatic and extra-hepatic) and experimental factors contributing to variations in pathway function. Given that the interplay between lipid homeostasis and inflammation has been considered a key factor in NASH pathophysiology since its initial description in 1980 [21], additional detail is given to well-recognized and emerging mechanisms through which alterations in mitochondrial oxidative metabolism not only impact lipid breakdown but also govern the inflammatory response underlying disease development and progression.

Section snippets

Overview of hepatic lipotoxicity and inflammation

A chronic excess of liver lipids and the resulting lipotoxicity drives the pathophysiology of NAFLD [22]. The accumulation of ‘toxic’ lipids or associated metabolic products instigate and exacerbate the inflammatory and fibrotic features of the disease through the promotion of organelle dysfunction and/or molecular signaling mechanisms [22]. The list of proinflammatory metabolites arising from lipid metabolism is continually increasing, however, the most frequently investigated metabolites

Overview of mitochondrial oxidative metabolism in NAFLD pathogenesis

Fatty acids can be catabolized in microsomes, peroxisomes, and mitochondria [18], [32]. Mitochondrial oxidative metabolism is the primary catabolic process for fatty acids and refers to a cluster of pathways including β-oxidation, citric acid cycle (CAC) flux, oxidative phosphorylation, and, in the liver, ketogenesis [18], [32]. Nutrient flux through each of the mitochondrial oxidative metabolism pathways has been reported to increase, decrease, or remain unchanged in NAFLD (Fig. 1). An

Conclusions and future perspectives

NAFLD is a multifactorial disease characterized by a chronic imbalance between hepatic lipid supply, accretion, and disposal. This impaired lipid homeostasis precipitates the accumulation of toxic lipids and related metabolites that promote inflammatory and fibrotic responses mediating the progressive pathophysiology of the disease. The dysregulation of lipid catabolism in mitochondrial oxidative metabolism pathways is a critical component of inadequate lipid disposal and, consequently,

CRediT authorship contribution statement

Curtis C. Hughey: Conceptualization, Writing – original draft, Writing – review & editing, Visualization. Patrycja Puchalska: Writing – review & editing, Visualization. Peter A. Crawford: Conceptualization, Writing – review & editing.

Declaration of competing interest

PAC has served as a consultant for Pfizer Inc., Abbott Laboratories, and Janssen Research & Development.

Acknowledgments

This work was supported by NIH grants DK091538 (PAC) and AG069781 (PAC), and an American Cancer Society Institutional Research Grant IRG-21-049-61-IRG131 (CCH). Figures were created with BioRender.com.

References (218)

  • A.M. Lundsgaard et al.

    Glucometabolic consequences of acute and prolonged inhibition of fatty acid oxidation

    J. Lipid Res.

    (2020)
  • J. Lee et al.

    Loss of hepatic mitochondrial long-chain fatty acid oxidation confers resistance to diet-induced obesity and glucose intolerance

    Cell Rep.

    (2017)
  • N.E. Sunny et al.

    Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease

    Cell Metab.

    (2011)
  • K.F. Petersen et al.

    Assessment of hepatic mitochondrial oxidation and pyruvate cycling in NAFLD by (13)C magnetic resonance spectroscopy

    Cell Metab.

    (2016)
  • R.J. Perry et al.

    Propionate increases hepatic pyruvate cycling and anaplerosis and alters mitochondrial metabolism

    J. Biol. Chem.

    (2016)
  • C.C. Hughey et al.

    Loss of hepatic AMP-activated protein kinase impedes the rate of glycogenolysis but not gluconeogenic fluxes in exercising mice

    J. Biol. Chem.

    (2017)
  • C.M. Hasenour et al.

    In vivo estimates of liver metabolic flux assessed by (13)C-propionate and (13)C-lactate are impacted by tracer recycling and equilibrium assumptions

    Cell Rep.

    (2020)
  • M.C. Scrutton

    Pyruvate carboxylase. Studies of activator-independent catalysis and of the specificity of activation by acyl derivatives of coenzyme A for the enzyme from rat liver

    J. Biol. Chem.

    (1974)
  • L. Miele et al.

    Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test

    Am. J. Gastroenterol.

    (2003)
  • C.C. Hughey et al.

    Glycine N-methyltransferase deletion in mice diverts carbon flux from gluconeogenesis to pathways that utilize excess methionine cycle intermediates

    J. Biol. Chem.

    (2018)
  • C.C. Hughey et al.

    Dysregulated transmethylation leading to hepatocellular carcinoma compromises redox homeostasis and glucose formation

    Mol Metab

    (2019)
  • F.I. Rome et al.

    Disrupted liver oxidative metabolism in glycine N-methyltransferase-deficient mice is mitigated by dietary methionine restriction

    Mol Metab

    (2022)
  • E. Desideri et al.

    Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity

    Cancer Lett.

    (2015)
  • N. Raimundo et al.

    Revisiting the TCA cycle: signaling to tumor formation

    Trends Mol. Med.

    (2011)
  • K. Sajnani et al.

    Genetic alterations in Krebs cycle and its impact on cancer pathogenesis

    Biochimie

    (2017)
  • A.S. Williams et al.

    Integrin alpha1-null mice exhibit improved fatty liver when fed a high fat diet despite severe hepatic insulin resistance

    J. Biol. Chem.

    (2015)
  • I.O. Goncalves et al.

    Exercise alters liver mitochondria phospholipidomic profile and mitochondrial activity in non-alcoholic steatohepatitis

    Int. J. Biochem. Cell Biol.

    (2014)
  • J. Teodoro et al.

    Decreased ANT content in zucker fatty rats: relevance for altered hepatic mitochondrial bioenergetics in steatosis

    FEBS Lett.

    (2006)
  • M. Perez-Carreras et al.

    Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis

    Hepatology

    (2003)
  • C. Koliaki et al.

    Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis

    Cell Metab.

    (2015)
  • Z.M. Younossi et al.

    Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes

    Hepatology

    (2016)
  • N. Chalasani et al.

    The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases

    Hepatology

    (2018)
  • N. Chalasani et al.

    The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

    Hepatology

    (2012)
  • F. Nassir et al.

    Pathogenesis and prevention of hepatic steatosis

    Gastroenterol. Hepatol. (N Y)

    (2015)
  • N. Alkhouri et al.

    Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal, expert rev

    Gastroenterol. Hepatol.

    (2009)
  • M.E. Rinella

    Nonalcoholic fatty liver disease: a systematic review

    JAMA

    (2015)
  • S.L. Friedman et al.

    Mechanisms of NAFLD development and therapeutic strategies

    Nat. Med.

    (2018)
  • A. Suzuki et al.

    Nonalcoholic steatohepatitis

    Annu. Rev. Med.

    (2017)
  • M.S. Ascha et al.

    The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

    Hepatology

    (2010)
  • B. Mohamad et al.

    Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis

    Hepatol. Int.

    (2016)
  • R.J. Wong et al.

    Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S

    Hepatology

    (2014)
  • T.G. Cotter et al.

    Nonalcoholic steatohepatitis after liver transplantation

    Liver Transpl.

    (2020)
  • Z.M. Younossi et al.

    The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

    Hepatology

    (2016)
  • N. Alkhouri et al.

    An update on the pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications

    Clin. Liver Dis. (Hoboken)

    (2018)
  • G.I. Smith et al.

    Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease

    J. Clin. Invest.

    (2020)
  • J. Ludwig et al.

    Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

    Mayo Clin. Proc.

    (1980)
  • I. Pierantonelli et al.

    Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH

    Transplantation

    (2019)
  • G. Musso et al.

    Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis

    Gastroenterology

    (2018)
  • H. Malhi et al.

    Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease

    Semin. Liver Dis.

    (2008)
  • G.C. Farrell et al.

    Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease

    Adv. Exp. Med. Biol.

    (2018)
  • Cited by (15)

    View all citing articles on Scopus
    View full text